Apollo Hospitals Enterprise Limited — PPTs, 30-05-2025: Investor Presentation

1. Financial Highlights:

Consolidated revenue rose 14% YoY to ₹21,794 Cr, driven by Healthcare Services (+13%), Diagnostics & Retail Health (+14%), and Digital Health & Pharmacy Distribution (+16%). EBITDA increased 26% YoY to ₹3,022 Cr, with stable 24% margin in Healthcare Services, Diagnostics margin improving to about 10%, and Digital Health & Pharmacy Distribution achieving EBITDA profitability after cost cuts. PAT jumped 61% YoY to ₹1,446 Cr due to margin gains and volume growth. Healthcare Services saw 67% bed occupancy (+200 bps) and 7% growth in average revenue per inpatient (₹1.71 L). Gross debt is ₹2,609 Cr with net debt stable, supporting ongoing expansions.

2. Strategic Initiatives & Growth Drivers:

Ramp-up continues with 45 hospitals and 8,025 beds operational; key metro and Tier-1 city expansion projects in Gachibowli, Mumbai Worli, and Chennai OMR with over ₹800 Cr capex planned through FY26. Diagnostics added 110 advanced assays to strengthen offerings. Digital investments include an AI-enabled Clinical Intelligence Engine and a pharmacy network scaled to 6,600+ outlets with 40 million users. Partnership with Eli Lilly to launch diabetes and weight management drugs complements preventive care expansion in primary clinics. Integration of Keimed boosts omni-channel pharmacy distribution and private label scale.

3. Business Developments:

Apollo Healthco secured ₹2,475 Cr from Advent International for phased Keimed merger targeting ₹25,000 Cr revenue and 7-8% EBITDA margin in 3 years. Telehealth offerings expanded via Apollo 24|7, AI-powered Ask Apollo, and insurance products with 12 insurers onboard. Clinical milestones include landmark transplants and pediatric surgeries. New contracts like Assam PPP dialysis and a partnership with Dabur for dental segment growth further diversify business.

4. Market Position & Competitive Advantage:

Largest pan-India hospital chain with 73 facilities and 10,200+ beds, enabling high utilization and superior case-mix. Leadership in complex care is evidenced by 25,000+ transplants, creating a strong clinical moat. Combined Apollo Healthco-Keimed presence commands 70,000+ pharmacies plus a broad digital ecosystem. Diagnostics and preventive care expansions enhance patient retention and cross-selling, supporting an integrated continuum of care model.

5. Investor Implications:

Diverse revenue drivers, margin expansion, and digital transformation underpin positive growth potential. Strong balance sheet plus Advent partnership back aggressive capex and inorganic pharmacy growth. Execution risks include timely commissioning of hospital expansions and smooth Keimed integration. Digital HealthCo turning profitable marks a value inflection for the group. Clinical leadership and patient-centric innovation sustain Apollo’s organized healthcare dominance.